Kumar Neil

Chief Executive Officer, DirectorBridgeBio Pharma, Inc. (BBIO) · full profile →Form 4 · filed Aug 20, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$3.7M
Net Open-Market Flow
-$3.7M
Transactions
7
7 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 19, 2026Sell(S)8K$83.86$679K508K
Aug 19, 2026Sell(S)2K$84.69$152K506K
Aug 19, 2026Sell(S)100$85.65$9K506K
Aug 18, 2026Sell(S)2K$81.15$154K276K
Aug 18, 2026Sell(S)1K$83.77$100K243K
Aug 18, 2026Sell(S)17K$82.21$1.4M259K
Aug 18, 2026Sell(S)15K$82.99$1.2M245K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001470831-26-000848) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Build on these Form 4 transactions

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.